Moreno, C. http://orcid.org/0000-0003-0541-4846
,
Parellada, M.
MacDowell, K. S.
García-Bueno, B.
Cabrera, B.
González-Pinto, A.
Saiz, P.
Lobo, A.
Rodriguez-Jimenez, R.
Berrocoso, E.
Bernardo, M.
Leza, J. C.
Funding for this research was provided by:
CIBERSAM (CIBERSAM Intramural Projects 2010 (P02), ERDF Funds from the European Commission, “A way of making Europe”)
Instituto de Salud Carlos III (PI08/0208,, PI 11/00325, PI12/01303, PI14/02069, PI17/02227)
Madrid Regional Government (B2017/BMD-3740 AGES-CM-2)
European Union Structural Funds and European Union Seventh Framework Program (FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN), FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY))
Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d’Economia i Coneixement (2014SGR441)
Article History
Received: 10 October 2018
Accepted: 9 February 2019
First Online: 6 March 2019
Conflict of interest
: C Moreno reports grants from European Union Funds, Instituto de Salud Carlos III Spanish Ministry of Economy and Competitiveness, and consultancy for Janssen, Servier, Nuvelution, Otsuka and Lundbeck unrelated to the submitted work; M Parellada reports grants from Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, during the conduct of the study; grants from CIBERSAM, grants from Fundación Alicia Koplowitz, Horizon 2020 and consultancy for Servier, unrelated to the submitted work; A Gonzalez-Pinto has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Janssen-Cilag, Lundbeck, Merck, Otsuka, Pfizer, Sanofi-Aventis, Servier, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), the Basque Governement, the Stanley Medical Research Institute, and Wyeth.; P Saiz has been a consultant to or has received honoraria or grants from Adamed, AstraZeneca, Brainpharma, Bristol-Myers Squibb, CIBERSAM, Esteve, European Comission, Ferrer inCode, GlaxoSmithKline, Instituto de Salud Carlos III, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Pfizer, Plan Nacional Sobre Drogas, Rovi and Servier.; A Lobo reports personal fees from Lundbeck, personal fees from Lilly, unrelated to the submitted work; R Rodriguez-Jimenez has been a consultant for, spoken at activities of, or received grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES), Janssen Cilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste; M Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Almirall, AMGEN, Boehringer, Eli Lilly, Ferrer, Forum Pharmaceuticals, Gedeon, Hersill, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Roche, Servier and has obtained research funding from the Spanish Ministry of Health, the Spanish Ministry of Science and Education, the Spanish Ministry of Economy and Competiveness, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), by the Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and the 7th Framework Program of the European Union. The remaining authors have nothing to disclose apart from grants from National or Regional public scientific agencies.